1. A phase III trial comparing doxorubicin and docetaxel (AT) to doxorubicin and cyclophosphamide (AC) as first line therapy for MBC;Nabholtz;Proc Am Soc Clin Oncol,1999
2. A phase III randomized trial comparing docetaxel (T), doxorubicin (A), and cyclophosphamide (C) (TAC) to FAC as first-line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC);Nabholtz;Proc Am Soc Clin Oncol,2001
3. 2000 update of recommendations for the use of hemotopoietic colony-stimulating factors: evidence-based, clinical practice guidelines;Ozer;American Society of Clinical Oncology Growth Factors Expert Panel,2001
4. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity;Johnston;Semin Oncol,1998
5. Polychemotherapy for early breast cancer: an overview of the randomised trials;Group;Lancet,1998